Relationship Between LSD1 Expression and E-cadherin Expression in Prostate Cancer

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2015 Jan 29

PMID 25627913

Citations 17

Authors

Min Wang

Xiuheng Liu

Guanjun Jiang

Hui Chen

Jia Guo

Xiaodong Weng

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the relationship between the expression of LSD1 and E-cadherin in prostate cancer and their prognostic significance.

Methods: The expression of LSD1 and E-cadherin in prostate cancer was detected using immunohistochemistry, and the relationship between the expressions of these two molecules was analyzed by correlation analysis. Furthermore, LNCap cell line was treated with Pargyline (an inhibitor of LSD1), and Western blot was used to analyze LSD1 and E-cadherin expression.

Results: LSD1 expression increased significantly in prostate cancer specimens compared with benign prostatic hyperplasia (P < 0.05). Further analysis testified that LSD1 expression was positively correlated with higher Gleason Score, distant metastases, and poor prognosis (P < 0.05). Nevertheless, E-cadherin expression decreased significantly in prostate cancer specimens compared with benign prostatic hyperplasia (P < 0.05) and was negatively correlated with higher Gleason Score, distant metastases (P < 0.05). Correlation analysis revealed that LSD1 expression was negatively correlated with E-cadherin expression in prostate cancer (rs = -0.486, P = 0.001). Positive LSD1 expression and negative E-cadherin expression were significantly correlated with high 2-year progression (occurrence of castration-resistant prostate cancer) rate and low 5-year survival rate (P < 0.05). Moreover, Pargyline inhibited activity of LSD1 and up-regulated E-cadherin expression.

Conclusion: High LSD1 expression combined with low E-cadherin expression might be predictors of prostate cancer progression and metastasis. Inhibition of LSD1 may be a potential therapeutic target for prevention of prostate cancer.

Citing Articles

Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.

Ahmed K, Sheikh A, Fatima S, Ghulam T, Haider G, Abbas F Sci Rep. 2024; 14(1):10315.

PMID: 38705879 PMC: 11070424. DOI: 10.1038/s41598-024-60538-0.

LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.

Yin Z, Liu S, Yang X, Chen M, Du J, Liu H Molecules. 2023; 28(14).

PMID: 37513188 PMC: 10383809. DOI: 10.3390/molecules28145315.

Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells.

Yan G, Zhang H, Li Y, Miao G, Liu X, Lv Q Invest New Drugs. 2023; 41(1):134-141.

PMID: 36692618 DOI: 10.1007/s10637-023-01330-1.

Design Two Novel Tetrahydroquinoline Derivatives against Anticancer Target LSD1 with 3D-QSAR Model and Molecular Simulation.

Xu Y, Fan B, Gao Y, Chen Y, Han D, Lu J Molecules. 2022; 27(23).

PMID: 36500451 PMC: 9739212. DOI: 10.3390/molecules27238358.

Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity.

Fioravanti R, Rodriguez V, Caroli J, Chianese U, Benedetti R, Di Bello E J Enzyme Inhib Med Chem. 2022; 37(1):973-985.

PMID: 35317680 PMC: 8942502. DOI: 10.1080/14756366.2022.2052869.

References

Hay E . An overview of epithelio-mesenchymal transformation. Acta Anat (Basel). 1995; 154(1):8-20. DOI: 10.1159/000147748. View

Kahl P, Gullotti L, Heukamp L, Wolf S, Friedrichs N, Vorreuther R . Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006; 66(23):11341-7. DOI: 10.1158/0008-5472.CAN-06-1570. View

Yip W, Seow H . Activation of phosphatidylinositol 3-kinase/Akt signaling by EGF downregulates membranous E-cadherin and β-catenin and enhances invasion in nasopharyngeal carcinoma cells. Cancer Lett. 2011; 318(2):162-72. DOI: 10.1016/j.canlet.2011.12.018. View

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Metzger E, Imhof A, Patel D, Kahl P, Hoffmeyer K, Friedrichs N . Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 2010; 464(7289):792-6. DOI: 10.1038/nature08839. View

Brooke G, Bevan C . The role of androgen receptor mutations in prostate cancer progression. Curr Genomics. 2009; 10(1):18-25. PMC: 2699836. DOI: 10.2174/138920209787581307. View

Ruizeveld de Winter J, Janssen P, Sleddens H, Trapman J, Brinkmann A, Santerse A . Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol. 1994; 144(4):735-46. PMC: 1887232. View

Lin T, Ponn A, Hu X, Law B, Lu J . Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition. Oncogene. 2010; 29(35):4896-904. PMC: 3093107. DOI: 10.1038/onc.2010.234. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

10.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

11.

Schulte J, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R . Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009; 69(5):2065-71. DOI: 10.1158/0008-5472.CAN-08-1735. View

12.

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J . The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000; 2(2):84-9. DOI: 10.1038/35000034. View

13.

Hayami S, Kelly J, Cho H, Yoshimatsu M, Unoki M, Tsunoda T . Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2010; 128(3):574-86. DOI: 10.1002/ijc.25349. View

14.

Metzger E, Wissmann M, Yin N, Muller J, Schneider R, Peters A . LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005; 437(7057):436-9. DOI: 10.1038/nature04020. View

15.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View

16.

Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R . Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659. PMC: 4892125. DOI: 10.1016/j.cell.2009.06.034. View

17.

Jie D, Zhongmin Z, Guoqing L, Sheng L, Yi Z, Jing W . Positive expression of LSD1 and negative expression of E-cadherin correlate with metastasis and poor prognosis of colon cancer. Dig Dis Sci. 2013; 58(6):1581-9. DOI: 10.1007/s10620-012-2552-2. View

18.

Friedl P, Alexander S . Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011; 147(5):992-1009. DOI: 10.1016/j.cell.2011.11.016. View

19.

Mohler J, Gregory C, Ford 3rd O, Kim D, Weaver C, Petrusz P . The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004; 10(2):440-8. DOI: 10.1158/1078-0432.ccr-1146-03. View

20.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View